- Home
- ANGO
ANGO
AngioDynamics Inc.
as 11-08-2024 1:30pm EST
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | LATHAM |
| Market Cap: | 271.1M | IPO Year: | 2004 |
| Target Price: | $12.00 | AVG Volume (30 days): | 530.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.26 - $8.25 | Next Earning Date: | 10-03-2024 |
| Revenue: | $292,726,000 | Revenue Growth: | -12.85% |
| Revenue Growth (this year): | -4.73% | Revenue Growth (next year): | 7.69% |
Stock Insider Trading Activity of AngioDynamics Inc. (ANGO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Trowbridge Stephen A | ANGO | EVP and CFO | Oct 8 '24 | Buy | $5.86 | 1,700 | $9,962.00 | 172,711 | |
| Clemmer James C | ANGO | President and CEO | Oct 7 '24 | Buy | $6.03 | 20,000 | $120,600.00 | 681,582 | |
| Nighan Warren JR | ANGO | SVP Quality and Regulatory | Oct 7 '24 | Buy | $6.09 | 868 | $5,285.12 | 45,777 |
Latest AngioDynamics Inc. News
ANGO Breaking Stock News: Dive into ANGO Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
Zacks
7 days ago
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade
Zacks
9 days ago
GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
Simply Wall St.
10 days ago
Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 77% over the last three years
Zacks
10 days ago
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
Clinical Trials Arena
15 days ago
AngioDynamics launches long-term study of NanoKnife for prostate cancer
Zacks
16 days ago
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
Business Wire
16 days ago
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
Compare ANGO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANGO AngioDynamics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.